2002
DOI: 10.1590/s1413-86702002000300004
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Problems with resistance to antifungal drugs have emerged due to an increase in the incidence of systemic fungal infections and widespread use of antifungal agents. Accordingly, efforts have been made to develop adequate fungal susceptibility tests. The ideal test should have high intra and inter-laboratory reproducibility, good correlation with the clinical outcome, and should be easy to perform. While no such test has yet been developed, advances have been made. Over the past decade, many reports of fungal r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
10
0
2

Year Published

2006
2006
2017
2017

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(13 citation statements)
references
References 50 publications
1
10
0
2
Order By: Relevance
“…The underlying medical conditions for the isolates were vaginal discharge, retroviral disease and pelvic inflammatory discharge. On most urine samples, the clinical diagnosis was stated as illegible thus making it difficult to ascertain if the presence of yeast in urine represents a true infection or merely colonization and contamination of the bladder (26). …”
Section: Discussionmentioning
confidence: 99%
“…The underlying medical conditions for the isolates were vaginal discharge, retroviral disease and pelvic inflammatory discharge. On most urine samples, the clinical diagnosis was stated as illegible thus making it difficult to ascertain if the presence of yeast in urine represents a true infection or merely colonization and contamination of the bladder (26). …”
Section: Discussionmentioning
confidence: 99%
“…The causal agents were mostly non-albicans Candida species, in particular C. glabrata, C. parapsilosis and C. krusei (Nucci and Colombo, 2002;Sharma et al, 2009;Zhang et al, 2014). Although fluconazole was widely indicated for the treatment of infections caused by Candida species, today it is considered ineffective against C. krusei and the therapeutic response regarding C. glabrata is rather variable (Rodriguez-Tudela et al, 2007).…”
Section: Discussionmentioning
confidence: 99%
“…The development of resistance to azole antifungal drugs, especially to fluconazole and itraconazole, is an emerging trend that may threaten their clinical effectiveness. Resistance to one azole is usually associated with cross‐resistance to other azoles; therefore the treatment of candidiasis has been problematic 10–14 …”
Section: Introductionmentioning
confidence: 99%
“…Resistance to one azole is usually associated with cross-resistance to other azoles; therefore the treatment of candidiasis has been problematic. [10][11][12][13][14] Benzoxazole derivatives are amongst the most thriving molecular prototypes for the development of new antifungal agents. [15][16][17] 2-(2¢-Hydroxy-5¢-aminophenyl)benzoxazole (HAMBO) ( Fig.…”
Section: Introductionmentioning
confidence: 99%